CardioDx Announces Positive Results From Clinical Utility Study Evaluating the Corus(R) CAD Blood Test's Influence on Clinical Decision-Making in the Assessment of Obstructive Coronary Artery Disease in Women
April 01, 2015 08:00 ET
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Apr 1, 2015) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a new study examining the...
National Panel of Multidisciplinary Experts Addresses the Unmet Needs in Assessing Coronary Artery Disease in Women
March 11, 2015 08:00 ET
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Mar 11, 2015) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of "The Diagnosis of CAD in...
It's Time to Spread the Word(TM) About Coronary Artery Disease and Women's Health
February 02, 2015 08:00 ET
|
CardioDx
WASHINGTON, DC and RED BANK, NJ--(Marketwired - Feb 2, 2015) - HealthyWomen and the National Association of Nurse Practitioners in Women's Health are partnering with CardioDx on a new patient...
CardioDx Raises $35 Million in Equity Financing
December 18, 2014 08:30 ET
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Dec 18, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the close of $35 million in total equity...
CardioDx Announces Results of Study Demonstrating the Benefits of the Corus CAD Gene Expression Test Use in an African American Patient Population
October 20, 2014 08:30 ET
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Oct 20, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of...
CardioDx Announces Aetna and Coventry Health Coverage for Corus(R) CAD Gene Expression Test
July 07, 2014 07:00 ET
|
CardioDx
REDWOOD CITY, CA--(Marketwired - Jul 7, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, confirmed today that Aetna has established a clinical policy...
New Study Results Further Reinforce That the Corus(R) CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions for Patients With Suspected Obstructive Coronary Artery Disease
May 05, 2014 09:50 ET
|
CardioDx
PALO ALTO, CA--(Marketwired - May 5, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the REGISTRY I study,...
CardioDx Announces New Leadership Appointments
April 28, 2014 17:52 ET
|
CardioDx
PALO ALTO, CA--(Marketwired - Apr 28, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today that diagnostics industry veterans Melinda...
CardioDx and Medison Israel Enter Into an Exclusive Corus(R) CAD Product Marketing and Sales Agreement
April 09, 2014 08:00 ET
|
CardioDx
PALO ALTO, CA and PETACH TIKVA, ISRAEL--(Marketwired - Apr 9, 2014) - CardioDx, Inc. and Medison today announced they have entered into an agreement granting Medison Israel the exclusive right to...
New Patient Registry Study Reinforces the Value of the Corus(R) CAD Gene Expression Test in Helping Clinicians Reduce Unnecessary Cardiac Testing in Patients With Suspected Obstructive Coronary Artery Disease
April 03, 2014 08:00 ET
|
CardioDx
PALO ALTO, CA--(Marketwired - Apr 3, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced interim results of a registry study examining...